相关实验视频

Updated: Jul 11, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

针对MRD和风险调整的AML的个人化分层治疗

Yijing Zhao¹, Hanfei Guo^2,3, Yingjun Chang¹

¹Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

|November 16, 2023

概括

在急性髓性白血病 (AML) 中,可测量的残留疾病 (MRD) 监测对于缓解评估和复发预测至关重要. 本综述阐明了基于2022年欧洲白血病网络指南的MRD技术,样本类型和时间.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床诊断临床诊断临床诊断

背景情况:

可测量的残留性疾病 (MRD) 是急性髓性白血病 (AML) 的重要生物标志物,用于评估缓解,预测复发和指导治疗.
目前面临的挑战包括缺乏标准化技术,样本材料和MRD评估的最佳时间.
技术的进步需要全面的理解,以获得有效的临床应用.

研究的目的:

审查和总结目前的MRD评估方法,样本来源和AML评估频率.
为了使MRD评估与欧洲白血病网络 (ELN) 2022的风险类别保持一致.
为MRD技术的最佳利用和组合提供指导,并完善干预策略.

主要方法:

在AML中对MRD评估技术和样本材料的系统审查.
基于ELN 2022风险分层的MRD评估频率的分类.
开发一个精细的流程图,用于预防性干预的时间和途径.

主要成果:

各种MRD检测方法和合适的样本来源 (例如骨髓,外周血液) 的总结.
基于ELN 2022对AML患者的风险类别的MRD评估时间的建议.
强调结合不同的MRD技术的协同价值,以提高精度.

结论:

在AML中对MRD的评估是复杂的,需要标准化的方法和先进的技术.
以ELN 2022标准为指导的最佳MRD评估对于个性化治疗和改善患者结果至关重要.
需要进一步的研究来完全标准化MRD评估,并将其纳入AML管理的临床实践.

关键词:

可测量的残留疾病.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.风险分层的分层是风险分层.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...